Merck & Co., Inc. (BCBA:MRK)

Market Cap	256.83T
Revenue (ttm)	68.59T
Net Income (ttm)	18.71T
Shares Out	n/a
EPS (ttm)	7,381.51
PE Ratio	13.73
Forward PE	9.05
Dividend	503.41 (2.50%)
Ex-Dividend Date	Jun 13, 2025

Volume	636
Average Volume	4,986
Open	20,200
Previous Close	20,075
Day's Range	20,100 - 20,600
52-Week Range	16,950 - 37,175
Beta	0.40
RSI	64.58
Earnings Date	Jul 29, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD